Latest filing published 01 Aug 2022 for Kalaris Therapeutics, Inc., €14.7M.
Insider track record
No signal scores available.
ElevateBio, LLC: trading record in brief
ElevateBio, LLC discloses dealings in Kalaris Therapeutics, Inc. to SEC (Form 4). Between 3 August 2020 and 28 July 2022, the trades on record add up to 2 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 1 August 2022, the filings show a share grant worth €14.7M in Kalaris Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to ElevateBio, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,253,796 shares@ US$4.61100.0% of flowCommon StockSEC:0000899243-22-027169:0
- 13,420,970 sharesCommon StockSEC:0000899243-20-021579:0
2 of 2 declarations
